Drug Profile
Xevinapant - Debiopharm/Merck
Alternative Names: AT 406; Debio-1143; SMAC mimetic - Debio-1143Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Ascenta Therapeutics
- Developer 3SBio; Ascenta Therapeutics; Debiopharm; EMD Serono; Merck & Co; The Leukemia & Lymphoma Society
- Class Amides; Antineoplastics; Aza compounds; Benzene derivatives; Pyrroles; Radiation-sensitising agents; Small molecules
- Mechanism of Action Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Squamous cell cancer
- Phase II Ovarian cancer; Solid tumours
- Phase I Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer
- No development reported Acute myeloid leukaemia; Lymphoma; Triple negative breast cancer
- Discontinued Leukaemia
Most Recent Events
- 18 Jan 2024 Phase-I clinical trials in Squamous cell cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) in USA, Belgium, South Korea, Spain, Taiwan (PO) (NCT06056310)
- 16 Nov 2023 Memorial Sloan Kettering Cancer Center initiates a phase II trial for Memorial Sloan Kettering Cancer Center in USA (PO) (NCT06145412)
- 15 Nov 2023 Phase-II clinical trials in Squamous cell cancer (Late-stage disease, Adjuvant therapy) in Slovenia, Belgium and France (PO) (NCT05724602)